U.S. Court of Appeals for the Federal Circuit, 2010

In Re Omeprazole Patent Litigation

In Re Omeprazole Patent Litigation
U.S. Court of Appeals for the Federal Circuit · Decided October 15, 2010

In Re Omeprazole Patent Litigation

Opinion

NOTE: ThiS order is n0nprecedentia1.

United States Court of Appeals for the FederaI Circuit IN RE OMEPRAZOLE PATENT LITIGATION ASTRAZENECA AB, AKTIEBOLAGET HASSLE, KBI-E, INC., KBI, INC., AND ASTRAZENECArLP, Plaintiffs-Appellees, V. MYLAN LABORATORIES INC. (N0w KNOWN As MYLAN INC.), MYLAN PHARMACEUTICALS INC., LABORATORIOS DR. ESTEVE, S.A., AND ESTEVE QUIMICA, S.A., Defendan,ts-Appellants.

2010-1414 Appeal from the United States DiStrict C0urt for the S0uthern District of NeW Y0rk in case n0S. 00-CV-6749, 03-CV-6057, M-21-81, and MDL n0. 1291, Judge Barbara S. J0nes.

ON MOTION ORDER ASTRAZENECA AB V. MYLAN LABS 2 AstraZeneca AB, et al. move for a 30 day extension of tirne, until N0vember 15, 201U, to file their response brief and for a 4-day extension of time, until Dece1nber 3, 2010, for Mylan Laboratories, Inc., et al. to file their reply brief Up0n consideration thereof I'r ls ORnERED THAT: The motion is granted FoR THE CoURT UCT 1 5 2010 /s/ J an Horbal3[ Date J an H0rbaly Clerk _ cc: Errol B. Taylor, Esq.

James H. Wallace, Jr., Esq. lLED “~’ve2zrfe;.rast§:°" OCT 1 5 2010 .lAN HORBALY CLERK

Case-law data current through December 31, 2025. Source: CourtListener bulk data.